Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review.

Authors:
Rebecca Joseph
Rebecca Joseph
From the Departments of Biochemistry and Biophysics and
Corvallis | United States

Semin Arthritis Rheum 2016 08 9;46(1):133-41. Epub 2016 Mar 9.

Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. Electronic address:

Objectives: The aim of this systematic literature review was to summarize the current knowledge regarding the prevalence of, time to recovery from, and influence of glucocorticoid dose and duration on glucocorticoid-induced adrenal insufficiency (AI).

Methods: Eligible studies were original research articles, which included adult patients with an indication for glucocorticoids and measured adrenal function following exposure to systemic glucocorticoids. Searches were performed in Web of Science and MEDLINE, with further articles identified from reference lists. Screening was performed in duplicate. Data were extracted for each group of glucocorticoid-exposed patients within eligible studies. The reported proportion of patients with AI was summarized as median and inter-quartile range. Results were then stratified by daily dose, cumulative dose, duration of exposure and time since last glucocorticoid use. The risk of bias within and across studies was considered: for randomised controlled trials risk of bias was assessed using the tool developed by the Cochrane Collaboration.

Results: Overall, 73 eligible studies were identified out of 673 screened. The percentage of patients with AI ranged from 0% to 100% with a median (IQR) = 37.4% (13-63%). Studies were small-median (IQR) group size 16 (9-38)-and heterogeneous in methodology. AI persisted in 15% of patients retested 3 years after glucocorticoid withdrawal. Results remained widely distributed following stratification. AI was demonstrated at <5mg prednisolone equivalent dose/day, <4 weeks of exposure, cumulative dose <0.5g, and following tapered withdrawal.

Conclusions: The heterogeneity of studies and variability in results make it difficult to answer the research questions with confidence based on the current literature. There is evidence of AI following low doses and short durations of glucocorticoids. Hence, clinicians should be vigilant for adrenal insufficiency at all degrees of glucocorticoid exposure.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2016.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987145PMC
August 2016
24 Reads
2 Citations
3.925 Impact Factor

Publication Analysis

Top Keywords

eligible studies
12
dose duration
8
adrenal insufficiency
8
risk bias
8
patients
5
studies
5
dose cumulative
4
daily dose
4
stratified daily
4
median inter-quartile
4
inter-quartile range
4
range stratified
4
cumulative dose
4
exposure time
4
studies considered
4
considered randomised
4
bias studies
4
glucocorticoid risk
4
time glucocorticoid
4
duration exposure
4

Altmetric Statistics

Similar Publications